Betterlife Pharma Inc. · CSE:BETR
Betterlife Pharma — Investor Presentation (May 2021)
27 slides from Betterlife Pharma's investor presentation, May 26, 2021
Slide 1: Life Sciences Company with an Evolving Portfolio of Novel Psychedelic and Anti-Viral Drugs
Life Sciences Company with an Evolving Portfolio of Novel Psychedelic and Anti-Viral Drugs Investor Presentation 2021-05-26 1
Slide 2: Investment Highlights: Three Compelling & Differentiated Assets
Investment Highlights: Three Compelling & Differentiated Assets Second Generation (non-hallucinogenic) Psychedelics TD-0148A: 2-bromo-LSD (oral) Indication: Major depressive disorder (MDD) IND filing projected Q1 2022 IP: Two manufacturing patents that eliminate controlled substance regulatory
Slide 3: BetterLife Pipeline
BetterLife Pipeline Next Clinical Development Product Delivery Indication Current Status Milestone Projected NEURO-PSYCHIATRY Preclinical IND filing Q1 2022 TD-0148A 2-bromo-LSD Oral Major Depressive Disorder IND-enabling studies Start Ph 1 Q1 2022 Other Neuro-Psychiatric Early Preclinical TBD after
Slide 4: TD-0148A: 2-bromo-LSD
TD-0148A TD-0148A 2-bromo-LSD Potential Treatment of Major Depressive Disorders and Other Neuro-Psychiatric Disorders 4
Slide 5: TD-0148A: 2-bromo-LSD – Background
TD-0148A: 2-bromo-LSD – Background BOL-148 (2-bromo-LSD) o Currently made by brominating LSD o BOL-148 is not a controlled substance, but due to its synthesis from LSD, its manufacturing is regulated as for LSD o Was originally synthesized by Albert Hofmann, the chemist who invented LSD o BOL-148 sh
Slide 6: The TD-0148A Advantage: Benefits of LSD without the hallucinations
The TD-0148A Advantage: Benefits of LSD without the hallucinations + Not a controlled substance The Achilles Heel of Psychedelics 1 All psychedelics currently in development are hampered by two main issues which arise from their “hallucinogenic” properties: 1. Administration must be performed in spe
Slide 7: TD-0148 IP: Proprietary Synthesis (Issued) and Method of Use (Pending)
TD-0148 IP: Issued IP: Synthesis BetterLife synthesis patent for 2-Bromo-LSD eliminates regulatory Proprietary Synthesis (Issued) and hurdles and obviates the need for synthesizing the Schedule 1 controlled Method of Use (Pending) substance LSD and the need for using List 1 starting materials. TD- 0
Slide 8: TD-0148A: A Significant Market Opportunity
TD-0148A: A Significant Market Opportunity Depression and Other Neuro-Psychiatric Disorders Market Share, by Indication 1 o The global depression drugs market reached US$ 12.41 Billion in 2019. 2 o According to the WHO, depression is one of the leading causes of disability and is currently prevalent
Slide 9: TD-0148A Projected Indications
TD-0148A Projected Indications TD-0148A Lead Indication o MDD or TRD (treatment resistant depression) 1 TD-0148A Additional Potential Indications o Cluster headaches / migraines o PTSD o Severe anxiety o Neuropathic pain 1. Exact 1st indication will be based on data from the Ph 2s. 9
Slide 10: TD-0148A Development Plan Projections
TD-0148A Development Plan Projections Drug Delivery Indication Current Status IND Phase 1 Phase 2 Oral Ph 1 in Healthy Ph 2 in MDD TD-0148A Major Depressive Disorder Preclinical Filing projected (capsules) Subjects 1 Start Q4 2022 IND-enabling studies Q1 2022 Start Q1 2022 Oral Other Neuro-Psychiatr
Slide 11: TD-010: Dihydrohonokiol-B (DHH-B)
TD-010 TD-010 Dihydrohonokiol-B (DHH-B) Potential Treatment of Anxiety and other Neuro- Psychiatric Disorders 11
Slide 12: TD-010: Dihydrohonokiol (DHH-B) – The Background
TD-010: Dihydrohonokiol (DHH-B) – The Background Honokiol (the parent of DHH-B) o Magnolia bark extracts have been used in traditional Chinese medicines for centuries as anxiolytic (anti- anxiety medication) o Honokiol is the active anxiolytic ingredient of magnolia bark o Several animal studies on
Slide 13: TD-010 IP: Proprietary Formulation & Method of Use (Pending)
TD-010 IP: Filed IP (pending): Formulation Proprietary Formulation & Method of Use DHH-B is highly insoluble and therefore poorly bioavailable. BetterLife’s patented formulation improves bioavailability. (Pending) Formulations covered include oral capsules, tablets, sub- lingual etc delivery. Filed
Slide 14: TD-010: A Significant Market Opportunity
TD-010: A Significant Market Opportunity o Benzodiazepines market was valued at US$ 3.48 Billion in 2019 and is projected to reach US$ 4.15 Billion by 2027, growing at a CAGR of 2.25% from 2020 to 2027. 1 o Rise in prevalence of anxiety and seizures is a major driver of the global benzodiazepine dru
Slide 15: TD-010 Projected Indications
TD-010 Projected Indications TD-010 Lead Indication o Benzodiazepine dependency TD-010 Additional Potential Indications o Anxiety o Spasticity (e.g. in multiple sclerosis) 15
Slide 16: TD-010 Development Plan Projections
TD-010 Development Plan Projections Drug Delivery Indication Current Status IND Phase 1 Phase 2 Oral Benzodiazepine Filing projected Ph 1 in healthy subjects OR Ph 1-2 in patients 2 TD-010 Preclinical (capsules)1 Dependency Q1 2022 Start Q1 2022 IND-enabling studies Oral Other Neuro-Psychiatric (cap
Slide 17: AP-003: Interferon alpha-2b (IFNα2b) Inhalation
AP-003 AP-003 Interferon alpha-2b (IFN⍺2b) Inhalation Potential Treatment & Prophylaxis of COVID-19 17
Slide 18: Why AP-003?
Why AP-003? SARS-CoV-2 coronavirus causes COVID-19 SARS-CoV viruses block interferon production in infected cells, allowing the virus to continue replicating unabated¹ Treatment with interferon may overcome that block, restoring cells normal anti-viral activity Interferon alpha 2b (IFNa2b) is a pote
Slide 19: AP-003: Unique Market Position and Opportunity
AP-003: Unique Market Position and Opportunity o AP-003 is being developed as a novel interferon alpha-2b (IFN⍺2b) inhalation formulation o U of Texas, showed evidence of a direct anti-viral effect of interferon alpha against novel coronavirus in vitro. The study demonstrated around 10,000 fold redu
Slide 20: AP-003 Patent Pending Application Covers Composition, Formulation and Treatment
The pending patent application AP-003 Patent Pending Application Covers covers1: Formulation Composition, Formulation and Treatment • Altum’s patent pending proprietary Composition AP-003 formulation improves stability of the IFNa2b and is • All current IFNa2b are adapted to inhalation delivery manu
Slide 21: AP-003 Development Plan Projections
AP-003 Development Plan Projections Manufacturing / Drug Delivery Indication Pre-Clinical / IND Phase 1 Phase 2 IND enabling studies Inhalation Treatment Filing projected Ph 2 in US2 AP-003 + (nebulizer) Early Stage Covid-191 Dec 2021 Start Q1 2022 PoC Chilean Ph 1-2 Study (discussed below) o In 202
Slide 22: Leadership
— f= 2) — ® xe} © ® a Leadership BetterLife Pharma
Slide 23: Leadership Team
Leadership Team Management Advisors Ahmad Doroudian, PhD Founder, CEO Jeff Fellows, Regulatory Affairs 25+ years experience in finance, M&A, Founder of Merus Labs (NASDAQ: MSLI) Hooshmand Sheshbaradaran, PhD, Chief Operating Officer Thomas P. Laughren, M.D. Psychiatry 30+ years senior pharma executi
Slide 24: BetterLife Share Capital (as of May 26, 2021)
BetterLife Share Capital (as of May 26, 2021) Issued and Outstanding Exercise Price Common shares 61,294,517 N/A Restricted and performance 42,500 N/A stock units Stock options 1,600,000 C$0.63 – C$0.77 440,000 C$1.33 – C$1.80 195,000 C$2.40 – C$2.60 619,557 C$3.09 – C$4.00 Warrants 6,386,298 C$0.60
Slide 25: Thank You
BLOCKCHAIN Thank You Contact: CEO: Ahmad Doroudian, Ph.D BetterLife Pharma Inc. 300 - 1275 West 6th Avenue Vancouver, BC V6H 1A6 Canada. Tel: 604 221-0595 Ahmad.Doroudian@blifepharma.com 25
Slide 26: Risk Factors
Risk Factors An investment in our securities is speculative and involves a high degree of risk. Prospective investors should carefully consider, together with other We have no assurance that a viable, economic path to regulatory approval for our proposed products in Canada, the U.S. and other regula
Slide 27: Risk Factors
Risk Factors to acquire, facilities for the production of our proposed products. There can be no assurance that we will be able to source or develop adequate We depend upon licenses from third parties and the maintenance of licenses is necessary for our success. manufacturing capabilities for suffic